Article Text

Download PDFPDF

TP022/#997  Sentinel-node biopsy in early stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY)
  1. Camilla Nero1,
  2. Nicolò Bizzarri1,
  3. Stefano Di Berardino1,
  4. Francesca Sillano1,
  5. Giuseppe Vizzielli2,
  6. Francesco Cosentino3,
  7. Virginia Vargiu1,
  8. Pierandrea De Iaco4,
  9. Myriam Perrone4,
  10. Enrico Vizza5,
  11. Benito Chiofalo5,
  12. Stefano Uccella6,
  13. Fabio Ghezzi7,
  14. Luigi Carlo Turco1,
  15. Giacomo Corrado1,
  16. Diana Giannarelli1,
  17. Tina Pasciuto1,
  18. Anna Fagotti1 and
  19. Giovanni Scambia1
  1. 1Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Ginecologia Oncologica, Rome, Italy
  2. 2University of Udine, Gynecologic Oncology, Udine, Italy
  3. 3Fondazione Giovanni Paolo II, Ginecologia Oncologica, Campobasso, Italy
  4. 4University of Bologna, Obstetrics and Gynecology, Bologna, Italy
  5. 5Istituto Nazionale Tumori Regina Elena-IFO, Ginecologia Oncologica, Roma, Italy
  6. 6AOUI-Università di Verona, Ginecologia Oncologica, Verona, Italy
  7. 7University of Insubria, Gynecologic Oncology Unit, Varese, Italy


Introduction Sentinel-lymph node biopsy has safely replaced lymphadenectomy in the staging of many solid cancers. The aim of this study was to evaluate the sensitivity and specificity of sentinel-lymph-node mapping compared with the gold standard of complete lymphadenectomy in detecting metastatic disease for early stage ovarian cancer.

Methods In the SELLY multicentre, prospective, phase II trial (EUDRACT 2019–001088-58) patients with presumed stage I-II epithelial ovarian cancer and planned for immediate or delayed minimally-invasive comprehensive staging were eligible for study inclusion. Patients received an injection of indocyanine green and sentinel-lymph-node mapping followed by pelvic and para-aortic lymphadenectomy. Seven centers from in Italy participated in the trial. Negative sentinel lymph nodes (by haematoxylin and eosin staining on sections) were ultra-staged with immunohistochemistry for cytokeratin. The primary endpoint, sensitivity of the sentinel-lymph-node-based detection of metastatic disease, was defined as the proportion of patients with node-positive disease with successful sentinel-lymph-node mapping who had metastatic disease correctly identified in the sentinel lymph node.

Current Trial Status Between March 2018 and July 2022, 176 patients were enrolled but only 174 received complete study interventions. 100 (58%) patients had successful mapping of at least one sentinel lymph node and 15 of them (15.0%) had positive nodes. Of the latter, 11 of 15 (73.3%) patients had a correct identification of the disease in the SLN. In detail, 7 out of 11 patients required ultrastaging protocol. 4 patients with node-positive disease had a negative SLN. Enrollment was closed on January 2023. Data analysis is about to be completed.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.